Dementia with Lewy bodies
Dementia with Lewy bodies (DLB), also known as Lewy body disease, is a neurodegenerative disease (a synucleinopathy to be specific) related to Parkinson disease (PD). It is reported as the second most common form of dementia following Alzheimer disease (AD), accounting for 15-20% of cases at autopsy.
Dementia with Lewy bodies presents in older patients (onset typically in 50-70 years of age), and is sporadic 1-2,7.
It is the second most common neurodegenerative cause of dementia in older patients, after Alzheimer disease, accounting for 15-20% of cases 3-4,7.
Typically patients first present with a frontal-type dementia with little in the way of memory deficits early in the course of the disease. Core features include 2,4,7:
- fluctuating cognitive impairment especially in executive function, attention and alertness
- visuospatial impairment, including visual hallucinations (detailed and vivid)
- concurrent parkinsonian symptoms may be present, but is less common, more frequently occurring years after the onset of dementia
Dementia with Lewy bodies vs Parkinson disease dementia
There are three entities to be distinguished in this gamut:
- Parkinson disease (PD)
- Parkinson disease dementia (PDD)
- Dementia with Lewy bodies (DLB)
The relationship between Parkinson disease and dementia with Lewy bodies is controversial, with some authors believing they are different manifestations of the same disease, whereas others (perhaps most) believe they are distinct entities 2. This notwithstanding, the main clinical distinction lies in the timing of symptoms.
In dementia with Lewy bodies, dementia precedes or accompanies parkinsonism (or at least becomes clinically evident within 12 months of presentation 5). Patients with Parkinson disease, on the other hand, will not infrequently also develop dementia. However, it typically occurs years after the onset of parkinsonian symptoms 1-2,5. Such cases are then referred to as Parkinson disease dementia (PDD); at least 12 months of Parkinsonism without dementia need to precede cognitive impairment 5,7.
Dementia with Lewy bodies vs Alzheimer disease
The prominent and fairly initially isolated memory disturbance seen early in the course of classical Alzheimer disease is the main distinguishing clinical feature. Posterior cortical atrophy variant of Alzheimer disease is harder to distinguish especially as it shares some clinical features.
Cognitive, movement and visual symptoms are treated with their respective medications. Treatment with neuroleptics may exacerbate Parkinsonian symptoms. Therefore a balance must be sought. Cholinesterase inhibitors may be more effective in Lewy body disease than in Alzheimer disease.
The characteristic feature of Lewy body disease (not surprisingly perhaps) is the accumulation of Lewy bodies throughout the brain, which results from alpha-synuclein conformation, which in turn lead to intranuclear inclusions.
Lewy bodies are seen in greatest concentrations in the midbrain, hypothalamus, basal ganglia, inferior olives, brainstem reticular formation, and dentate nuclei of the cerebellum 2.
Neurofibrillary tangles are also present, although unlike those found in Alzheimer disease, they lack an amyloid core 2.
MRI is the modality of choice to structurally image the brain. Functional imaging with SPECT/PET is also useful.
Unfortunately the literature is replete with studies showing atrophy in various parts of the brain without a clearly identified unique pattern. Most helpful in distinguishing DLB from other entities resulting in dementia is the absence of features of other diseases.
Features reported include 1-2,7:
- generalised decrease in cerebral volume most marked in
- frontal lobes
- parietotemporal regions
- enlargement of the lateral ventricles
- relatively focal atrophy of the 4
Occipital hypoperfusion on SPECT/PET 1 and may aid in differentiation from other types of dementia, especially Alzheimer disease 8-9.
Treatment and prognosis
Unlike Parkinson disease, dementia with Lewy bodies respond less readily to L-dopa and also may have severe sensitivity reactions to neuroleptic drugs, such as rigidity, reduced consciousness, pyrexia, falling, postural hypotension and collapse 3.
Lewy body dementia also responds favourably to acetylcholinesterase inhibitors 6.
History and etymology
Lewy body inclusions were first discovered in the early 1900s by the German-born, American neurologist Frederic Lewy 10. However, the association of dementia with Lewy bodies was first discovered in 1976 by Kenji Kosaka, a Japanese psychiatrist and neuropathologist 11.
It is important to realise that there is significant overlap between many neurodegenerative diseases, and that a clear-cut distinction between entities is not always possible. In the case of dementia with Lewy bodies, this is particularly the case, with strong overlap between:
- clinical: may occasionally have a similar clinical presentation with a frontal type dementia or posterior cortical atrophy
- imaging: prominent involvement of hippocampi on imaging
- clinical: dementia is only a late feature, with parkinsonian symptoms having been present for many years 5
frontotemporal lobar degeneration
- clinical: usually younger onset, absent parkinsonian features, absent visual hallucinations
- imaging: more pronounced frontal/temporal atrophy; left-to-right asymmetry
- 1. Grossman RI, Yousem DM. Neuroradiology, the requisites. Mosby Inc. (2003) ISBN:032300508X. Read it at Google Books - Find it at Amazon
- 2. Kornienko VN, Pronin IN. Diagnostic Neuroradiology. Springer Verlag. (2008) ISBN:3540756523. Read it at Google Books - Find it at Amazon
- 3. Piggott MA, Marshall EF, Thomas N et-al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain. 1999;122 ( Pt 8) : 1449-68. doi:10.1093/brain/122.8.1449 - Pubmed citation
- 4. Whitwell JL, Weigand SD, Shiung MM et-al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain. 2007;130 (Pt): 708-19. doi:10.1093/brain/awl388 - Free text at pubmed - Pubmed citation
- 5. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125 (Pt): 391-403. doi:10.1093/brain/awf033 - Pubmed citation
- 6. Tiraboschi P, Salmon DP, Hansen LA et-al. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain. 2006;129 (Pt): 729-35. doi:10.1093/brain/awh725 - Pubmed citation
- 7. Taylor JP, O'Brien J. Neuroimaging of dementia with Lewy bodies. Neuroimaging Clin. N. Am. 2012;22 (1): 67-81, viii. doi:10.1016/j.nic.2011.11.001 - Pubmed citation
- 8. McKeith I, O'Brien J, Walker Z et-al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6 (4): 305-13. doi:10.1016/S1474-4422(07)70057-1 - Pubmed citation
- 9. Mollenhauer B, Förstl H, Deuschl G et-al. Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. Dtsch Arztebl Int. 2011;107 (39): 684-91. doi:10.3238/arztebl.2010.0684 - Free text at pubmed - Pubmed citation
- 10. Holdorff B. Friedrich Heinrich Lewy (1885-1950) and his work. J Hist Neurosci. 2002;11 (1): 19-28. doi:10.1076/jhin.18.104.22.16806 - Pubmed citation
- 11.KOSAKA K. Proceedings of the Japan Academy, Series B. 2014;90 (8): . doi:10.2183/pjab.90.301
Neurodegenerative diseases are legion and their classification just as protean. A useful approach is to divide them according to underlying pathological process, although even using this schema, there is much overlap and thus resulting confusion.
neurodegenerative MRI brain (an approach)
- measurements and ratios
- midbrain to pons area ratio (for PSP)
- Magnetic Resonance Parkinsonism Index (MRPI) (for PSP)
- frontal horn width to intercaudate distance ratio (FH/CC) (for Huntington disease)
- intercaudate distance to inner table width ratio (CC/IT) (for Huntington disease)
- scoring systems
- measurements and ratios
- typical/classical Alzheimer disease
- variant (e.g. posterior cortical atrophy)
- chronic traumatic encephalopathy (CTE)
- corticobasal degeneration
- frontotemporal lobar degeneration (FTLD) (not all are tau)
- Pick disease
- progressive supranuclear palsy (PSP)
- Alzheimer disease
- cerebral amyloidosis
- spinocerebellar ataxias
- Huntington disease
- hereditary spastic paraplegia
- amyotrophic lateral sclerosis (ALS)
- clinically unclassifiable parkinsonism (CUP)
- Unverricht-Lundborg disease
- prion diseases (not always included as neurodegenerative)